Press Releases

Cepheid Announces Partner Distribution Agreement With Medline

Further Broadens Reach of GeneXpert System into Non-Acute Market in United States

SUNNYVALE, Calif., April 21, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced an agreement with Medline, the largest privately held distributor of healthcare products in the United States, for the distribution of the GeneXpert® System and menu of Xpert® tests spanning healthcare associated infections, critical infectious disease, and sexual health. Under the terms of the non-exclusive agreement, Medline will begin offering the GeneXpert System to non-acute care laboratory customers in the United States, including long-term care facilities with moderately complex labs, physician-office laboratories, women's health and large multi-specialty clinics, urgent care facilities, community health centers, correctional facility laboratories, student health centers, STD clinics, and reference laboratories.

Using 'Diagnostics First' Could Help Preserve Effectiveness Of Life-Saving Antibiotics

Cepheid Highlights Role of Diagnostics as Valuable Tool in Growing Fight Against Antibiotic Resistance

SUNNYVALE, Calif. and AMSTERDAM, April 11, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced the launch of its 'Diagnostics First' campaign to raise awareness for the use of accurate and fast diagnostic tests to inform optimal treatment decisions and avoid over-prescription of the world's limited arsenal of antibiotics.

Cepheid Announces European Approval Of Xpert MRSA Next Generation (NxG) Screening Test

The Number One, On-Demand Molecular Test for MRSA Colonization is Now Improved

SUNNYVALE, Calif., March 29, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced commercial availability, outside the United States, of Xpert® MRSA NxG, a next generation version of the market-leading molecular diagnostic test for Methicillin-Resistant Staphyloccus aureus (MRSA). Xpert MRSA NxG has been updated to identify mecA- and mecCcontaining MRSA strains and detect new and emerging SCCmec subtypes with enhanced performance. The assay has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. Xpert MRSA NxG is an important update to the menu of 23 tests available internationally to run on Cepheid's GeneXpert® System, the world's leading molecular diagnostic platform with over 10,000 systems deployed globally in both developed and emerging market countries.

Cepheid Recognizes World TB Day 2016 With Delivery Of 5,000th GeneXpert System To Support Global Fight Against Tuberculosis And Multi-Drug Resistant Tuberculosis

SUNNYVALE, Calif., March 24, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today recognized World TB Day 2016 with the delivery of the 5,000th GeneXpert® System to be deployed as part of the company's shared commitment, with partners including the Foundation for Innovative New Diagnostics (FIND) and USAID, to enable global access to industry-leading and potentially life-saving information from molecular diagnostic tests to patients regardless of geographic location.

Cepheid Announces First FDA-Cleared Test for Detection of Carbapenem Resistance Genes in Isolates of Multidrug Resistant 'Superbugs'

Xpert Carba-R Results in Less Than an Hour Help to Prevent and Manage Outbreaks

SUNNYVALE, Calif., March 9, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market Xpert® Carba-R, a qualitative in vitro diagnostic test for fast, accurate, and reproducible identification of 5 distinct families of carbapenem resistance genes that together represent the most common carbapenemases identified globally, including KPC, NDM, VIM, OXA-48 and IMP. Xpert Carba- R is the first FDA-cleared test for detection and differentiation of carbapenemase genes in pure bacterial isolates, previously shown to be non-susceptible to carbapenem antibiotics, which may be cultured from a wide range of clinical specimens, including blood cultures, urine, respiratory samples, abscesses and swab surveillance specimens.

Cepheid Delivers Milestone 10,000th GeneXpert System

Dean Street Express Expanding to Additional Locations using GeneXpert Infinity System

SUNNYVALE, Calif., March 7, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced the delivery of the 10,000th GeneXpert® System to the 10 Hammersmith Broadway Clinic in London, England.

Cepheid Announces Appointment of President and Chief Operating Officer and Welcomes Executive Vice President of Engineering and Operations

SUNNYVALE, Calif., Feb. 10, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that Warren Kocmond, formerly Executive Vice President and Chief Operating Officer, has been promoted to the position of President and Chief Operating Officer. In his new capacity, Mr. Kocmond's responsibilities have been expanded, and now include Global Commercial Operations in addition to Manufacturing Operations, Engineering, Technical Service and Customer Service. Mr. Kocmond will continue to report to John Bishop, Cepheid's Chairman and Chief Executive Officer.

Cepheid Reports Fourth Quarter And Full Year 2015 Results

Commercial Clinical Grew 19%, or 21% in Constant Currency, Driven by Record Reagent Revenue and Record GeneXpert System Placements

SUNNYVALE, Calif., Feb. 2, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today reported revenue for the fourth quarter of 2015 of $147.0 million, representing growth of 12% from $131.5 million for the fourth quarter of 2014. Net loss was $(9.8) million, or $(0.14) per share, which compares to net loss of $(23.8) million, or $(0.34) per share, in the fourth quarter of 2014.

Cepheid Announces Diagnostic Collaboration With MedImmune And COMBACTE To Facilitate Clinical Trials Of New Monoclonal Antibodies To Prevent Serious Infectious Diseases

GeneXpert Systems and Xpert Tests Expected to Enhance Efficiency of Clinical Trials

SUNNYVALE, Calif., Jan. 13, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, and COMBACTE, a European public/private partnership set up to promote the development of new drugs in the anti-infectives field, to develop a series of rapid diagnostic tests to identify Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) in respiratory secretions of mechanically ventilated patients. These tests will be used to help identify patients for MedImmune's MEDI4893 and MEDI3902 clinical programs, which are being conducted within the COMBACTE consortium to explore the use of biologics in preventing ventilator associated pneumonia (VAP) infections in intensive-care-unit (ICU) patients.

USAID And Cepheid Plan Collaboration To Accelerate Global Diagnosis Of Multidrug- Resistant Tuberculosis

SUNNYVALE, Calif., Jan. 7, 2016 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that it has signed a Memorandum of Understanding (MOU) representing the intention of the company, working with the United States Agency for International Development (USAID), to support the White House's National Action Plan for Combating Multidrug-Resistant Tuberculosis. The National Action Plan identifies critical interventions to be taken by United States Government agencies and partners to reverse the worldwide spread of multidrug-resistant (MDR) tuberculosis (TB). The MOU is expected to be followed by a Collaborative Agreement between Cepheid and USAID setting out the details of this cooperation.